Summary
72 / 100 · Bulios Score
What speaks for it
- Out of every 100 SEK of revenue, 22 SEK is left as net profit.
- It earns 31 SEK a year on every 100 SEK of invested capital.
- It has no debt and holds 446.3M kr in cash.
- Revenue grew by 12% a year over the last 3 years.
What to watch
- The share price is above the Bulios Fair Price.
- It pays out more in dividends than it earns: 122% of profit.
- Earnings per share fell by 3.8% a year over the last 3 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 34.0 SEK for 1 SEK of yearly profit. Over the last five years it was 33.2 SEK on average.
Valuation in detailIs it growing?
SlowlyRevenue (SEK)
Diluted EPS (SEK)
- Analyst estimate
Revenue grew by 16% a year over 5 years. Over the last 3 years it grew by 12% a year.
Growth in detailDoes it make money?
Very wellWhere 100 SEK of revenue goes
- Cost of sales 27 SEK
- Research and development 7.4 SEK
- Sales and administration 38 SEK
- Taxes and other 6.1 SEK
- Net profit 22 SEK
Net profit, industry median (Drug Manufacturers - Specialty & Generic) 10 SEK
Out of every 100 SEK of revenue, 22 SEK is left as net profit.
Profitability in detailIs it financially healthy?
YesIt has no debt.
Financial health in detailDoes it pay a dividend?
Moderate, at risk- Yield
- 3.60%
- Paid out of profit
- 122%
- Raised in a row
- 2 years
You receive $0.42 per share a year. The payout is more than the company can comfortably cover.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.